Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiotherapy in Locally Advanced Cervical Squamous Cell Carcinoma
NCT04678791Phase 3Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in cervical squamous cell carcinoma (CSCC) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Progression-Free Survival at 3 years. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT04678791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678791.